Expressions of JNK and p-JNK in advanced prostate cancer and their clinical implications.
- Author:
Peng ZHANG
1
;
Jian HAN
1
;
Lei ZHENG
1
;
Ke-Nan WANG
1
;
Lian-Ming FAN
1
;
Hua-Dong XIE
1
;
Shu-Ren WANG
1
;
Tao JIANG
1
Author Information
1. Department of Urology and Andrology, The First Hospital Affiliated to Dalian Medical University, Dalian, Liaoning 116011, China.
- Publication Type:Journal Article
- Keywords:
apoptosis;
jun N-terminal kinase;
phosphorylation;
phosphorylation jun N-terminal kinase;
prostate cancer;
survival time
- MeSH:
Humans;
Immunohistochemistry;
JNK Mitogen-Activated Protein Kinases;
metabolism;
Male;
Neoplasm Grading;
Neoplasm Proteins;
metabolism;
Prognosis;
Prostate-Specific Antigen;
metabolism;
Prostatic Hyperplasia;
enzymology;
mortality;
pathology;
Prostatic Neoplasms;
enzymology;
mortality;
pathology
- From:
National Journal of Andrology
2017;23(4):309-314
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expressions of JNK and p-JNK in advanced prostate cancer (PCa) and benign prostatic hyperplasia (BPH) and their implications.
METHODS:Using immunohistochemistry, we detected the expressions of JNK and p-JNK proteins in 40 cases of paraffin wax-embedded PCa and 21 cases of BPH tissues and analyzed their relationships with advanced PCa and BPH as well as with the pathologic features of advanced PCa.
RESULTS:Statistically significant differences were not found in the positive expression rate of the JNK protein between BPH and PCa (42.86% vs 52.50%, P>0.05), non-metastatic and metastatic PCa (53.85% vs 51.85%, P >0.05), Gleason ≤7 and Gleason >7 (58.82% vs 47.82%, P >0.05), PSA ≤20 μg/L and PSA >20 μg/L (57.14% vs 51.52%, P >0.05), or survival >5 yr and survival ≤5 yr (60.00% vs 45.00%, P >0.05), nor in the expression level of p-JNK between BPH and PCa (33.33% vs 35.00%, P >0.05), non-metastatic and metastatic PCa (30.77% vs 37.03%, P >0.05), Gleason ≤7 and Gleason >7 (35.29% vs 34.78%, P >0.05), or PSA ≤20 μg/L and PSA >20 μg/L (43.75% vs 10.93%, P >0.05). However, the expression of p-JNK was significantly higher in the survival >5 yr than in the survival ≤5 yr group of the PCa patients (50.00% vs 20.00%, P <0.05).
CONCLUSIONS:PCa patients with highly expressed p-JNK have a longer survival time and the high positive rate of p-JNK is associated with the prognosis of PCa.
